Evolution of the Average Target: Evolus, Inc.

Evolution of the Target Price: Evolus, Inc.

Changes in Analyst Recommendations: Evolus, Inc.

971c38354a1ee722f97537e7f4.2dVclNFfGwERVhUCdVUNtUq9mFJjJJ-wLHyJjDfg1kU.gYIxxZ9mbWJ2EVpbGBB08DnI7TssUKnoZhX64gDZhHXtlAz-6SdXa0YsTA~d270e149c809c1be8535ebe8dcb8a592
11-12 Tandem Diabetes Care, Inc. Appoints Sandra Beaver to Board of Directors, Effective November 7, 2025 CI
25-04-17 BTIG Initiates Evolus at Buy With $21 Price Target MT
24-03-08 Mizuho Securities Adjusts Evolus Price Target to $23 From $20, Maintains Buy Rating MT
24-01-29 Barclays Upgrades Evolus to Overweight From Equalweight, Raises Price Target to $16 From $10 MT
23-08-03 HC Wainwright Adjusts Price Target on Evolus to $27 From $16, Maintains Buy Rating MT
23-06-07 Mizuho Securities Adjusts Evolus Price Target to $20 From $17, Maintains Buy Rating MT
23-05-26 Truist Securities Adjusts Price Target on Evolus to $18 From $14, Maintains Buy Rating MT
23-05-10 HC Wainwright Adjusts Price Target on Evolus to $16 From $15, Maintains Buy Rating MT
23-01-19 Mizuho Securities Adjusts Evolus' Price Target to $17 From $15, Keeps Buy Rating MT
22-06-23 Needham & Co Initiates Coverage on Evolus With Buy Rating, $18 Price Target MT
22-05-12 Barclays Upgrades Evolus to Equalweight From Underweight, Adjusts Price Target to $10 From $8 MT
22-01-20 Truist Securities Upgrades Evolus to Buy From Hold; Price Target is $11 MT
21-11-03 HC Wainwright Adjusts Evolus' Price Target to $15 From $22, Keeps Buy Rating MT
21-05-13 Evolus : Barclays Adjusts Evolus' Price Target to $7 From $8, Maintains Underweight Rating MT
21-05-06 Evolus : Mizuho Securities Upgrades Evolus to Buy From Neutral; Price Target is $15 MT
21-04-08 Evolus : HC Wainwright Adjusts Evolus' Price Target to $22 From $20, Maintains Buy Rating MT
21-03-30 Evolus : Mizuho Adjusts Evolus' Price Target to $15 From $9, Maintains Neutral Rating MT
21-03-24 Evolus : HC Wainwright Adjusts Evolus' Price Target to $20 From $18, Maintains Buy Rating MT
21-02-24 Evolus : Truist Securities Downgrades Evolus to Hold From Buy, Adjusts Price Target to $12 From $6 MT
21-02-22 Evolus : Barclays Adjusts Evolus' Price Target to $8 From $4, Reiterates Underweight Rating MT
21-02-22 Evolus : Cantor Fitzgerald Adjusts Evolus' Price Target to $20 From $11, Maintains Overweight Rating MT
21-02-22 Evolus : Mizuho Adjusts Evolus' Price Target to $9 From $5, Maintains Neutral Rating MT
21-02-22 Evolus : HC Wainwright Adjusts Evolus' Price Target to $18 From $6, Maintains Buy Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
- - - -
+11.96%
+1.66%
+8.26%
+3.24%
+0.76%
+31.03%
-10.16%
+4.82%
+8.05%
Average +6.62%
Weighted average by Cap. +7.26%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
9.090USD
Average target price
15.00USD
Spread / Average Target
+65.02%
High Price Target
20.00USD
Spread / Highest target
+120.02%
Low Price Target
12.00USD
Spread / Lowest Target
+32.01%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB